Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics, Inc. senior vice president and chief technical officer Benjamin Machinas Beneski reported a mandatory sale of common stock to cover taxes on vested restricted stock units. He sold 7,132 shares in a sell-to-cover transaction at a weighted average price of $2.60 per share, with individual sale prices ranging from $2.60 to $2.67. After this tax-related sale, he directly owned 203,040 shares of Allogene common stock. The filing notes this transaction was required under the company’s equity incentive plan and did not represent a discretionary trade by the executive.
Allogene Therapeutics, Inc. reported a Form 144 notice for 7,132 shares of Common Stock tied to the vesting of a restricted stock unit award on 02/28/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker and NASDAQ as the market.
Allogene Therapeutics, Inc. shareholder Arie Belldegrun reports beneficial ownership of 13,248,170 shares of common stock, equal to 5.8% of the company as of December 31, 2025. This total includes 3,885,280 shares issuable within 60 days upon exercise of stock options.
The filing aggregates shares held directly and through Bellco Legacy LLC, Bellco Legacy IV LLC, Vida Ventures LLC, Vida Ventures III, L.P., and Vida Ventures III-A, L.P. Ownership percentages are calculated using 224,730,144 Allogene shares outstanding as of November 4, 2025.
Pfizer Inc. reports beneficial ownership of 22,032,040 shares of Allogene Therapeutics, Inc. common stock, representing 9.0% of the class. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q. The lower ownership percentage in this amendment results solely from Allogene issuing more shares, not from Pfizer selling or buying stock. Pfizer and its listed executives report no transactions in Allogene shares during the prior 60 days.
Allogene Therapeutics, Inc. shareholder David D. Chang reports beneficial ownership of 12,101,223 shares of common stock, representing 5.2% of the company. This percentage is based on 224,730,144 shares outstanding as of November 4, 2025, as reported in Allogene’s Form 10-Q.
Dr. Chang’s reported holdings include 6,373,347 shares issuable within 60 days of December 31, 2025 upon exercise of stock options, as well as shares held through several California trusts. The Chang 2006 Family Trust holds 1,201,108 shares, and the JEC 2019 Trust and RTC 2019 Trust each hold 856,044 shares, all reported with shared or sole voting and dispositive powers as specified.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported new equity awards and a small share sale. On February 2, 2026, he sold 7,549 shares of common stock at a weighted average price of $1.73 solely to cover tax withholding on vesting restricted stock units, under a mandatory “sell to cover” arrangement rather than a discretionary trade. He received a stock option for 373,757 shares at $1.87 per share, vesting 25% on February 2, 2027 and the balance in 36 monthly installments. He was also granted 105,720 restricted stock units, each representing one share, vesting in four equal annual installments starting February 2, 2026, subject to continued service. Following these transactions, he directly owned 210,172 shares of common stock.
Allogene Therapeutics President and CEO David D. Chang reported new equity awards and a tax-related share sale. On February 2, 2026, he received a stock option for 1,387,931 shares of common stock at an exercise price of $1.87 per share, vesting 25% on February 2, 2027, with the rest vesting in 36 equal monthly installments. He also received 392,586 restricted stock units, each representing one share of common stock, vesting in four equal annual installments from February 2, 2026, subject to continued service. To cover tax withholding on RSU vesting, 95,269 shares of common stock were sold at a weighted average price of $1.80 in a mandated "sell to cover" transaction, which the filing states was not a discretionary trade. After these transactions, he directly beneficially owned 5,185,862 shares of common stock and additional indirect holdings through several family trusts.
Allogene Therapeutics’ chief financial officer Geoffrey M. Parker reported routine equity compensation activity and a tax-related share sale. On February 2, 2026, he sold 24,001 shares of common stock at a weighted average price of $1.76 solely to cover tax withholding on vesting restricted stock units, under a mandated “sell to cover” arrangement. Following this, he directly owned 1,252,795 common shares. On the same date, he received a stock option to buy 539,072 shares at an exercise price of $1.87 per share, vesting 25% on February 2, 2027 and the rest in 36 monthly installments. He also received 152,480 restricted stock units, each equal to one share of common stock, vesting in four equal annual installments starting February 2, 2026, subject to continued service.
Allogene Therapeutics SVP and General Counsel Douglas Earl Martin reported new equity awards and a related share sale. On February 2, 2026, he was granted a stock option covering 539,072 shares of common stock at an exercise price of $1.87 per share. Twenty‑five percent of this option will vest on February 2, 2027, with the remaining shares vesting in 36 equal monthly installments.
He also received 152,480 restricted stock units, each representing one share of common stock, which will vest in four equal annual installments starting February 2, 2026, subject to continued service. On the same date, he sold 22,900 shares of common stock at a weighted average price of $1.76 to cover tax withholding obligations from RSU vesting, and this was not a discretionary trade. After the sale, he directly beneficially owned 564,948 shares of common stock.
Allogene Therapeutics, Inc. SVP Finance Annie Yoshiyama reported new equity awards and a small tax-related share sale. On February 2, 2026, she received a stock option for 179,691 shares of common stock at an exercise price of $1.87 per share and an award of 50,827 restricted stock units (RSUs). The option vests 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments, while the RSUs vest in four equal annual installments starting from February 2, 2026, subject to continued service. On the same date, she sold 4,167 shares of common stock at a weighted average price of $1.72 solely to cover tax withholding on vesting RSUs, under a mandatory “sell to cover” arrangement, and reported owning 130,322 common shares directly afterward.